Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

crispr therapeutics ag - CRSP

CRSP

Close Chg Chg %
58.18 -1.30 -2.23%

Closed Market

56.88

-1.30 (2.23%)

Volume: 1.66M

Last Updated:

Dec 5, 2025, 4:00 PM EDT

Trade Now

Company Overview: crispr therapeutics ag - CRSP

CRSP Key Data

Open

$58.05

 Day Range

56.01 - 58.76

52 Week Range

30.06 - 78.48

 Market Cap

$5.54B

Shares Outstanding

95.30M

 Public Float

91.32M

Beta

1.73

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$5.58

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

2.53M

  

CRSP Performance

1 Week
 
 8.81%
 
1 Month
 
 5.55%
 
3 Months
 
 6.05%
 
1 Year
 
 11.18%
 
5 Years
 
 -60.57%
 

CRSP Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 30
Full Ratings ➔

About crispr therapeutics ag - CRSP

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRSP At a Glance

CRISPR Therapeutics AG
Baarerstrasse 14
Zug, Zug 6300
Phone 41-41-561-32-77 Revenue 37.31M
Industry Biotechnology Net Income -366,252,000.00
Sector Health Technology Employees 393
Fiscal Year-end 12 / 2025
View SEC Filings

CRSP Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 88.985
Price to Book Ratio 1.747
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -3.667
Enterprise Value to Sales 43.958
Total Debt to Enterprise Value 0.136

CRSP Efficiency

Revenue/Employee 94,946.565
Income Per Employee -931,938.931
Receivables Turnover 1.377
Total Asset Turnover 0.017

CRSP Liquidity

Current Ratio 22.068
Quick Ratio 22.068
Cash Ratio 21.688

CRSP Profitability

Gross Margin -247.079
Operating Margin -1,250.378
Pretax Margin -971.927
Net Margin -981.54
Return on Assets -16.381
Return on Equity -19.201
Return on Total Capital -16.989
Return on Invested Capital -17.259

CRSP Capital Structure

Total Debt to Total Equity 11.578
Total Debt to Total Capital 10.376
Total Debt to Total Assets 9.977
Long-Term Debt to Equity 10.683
Long-Term Debt to Total Capital 9.575
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Crispr Therapeutics Ag - CRSP

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
914.96M 1.20M 371.21M 37.31M
Sales Growth
+127,154.94% -99.87% +30,885.48% -89.95%
Cost of Goods Sold (COGS) incl D&A
17.95M 134.42M 150.09M 129.51M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
17.95M 24.17M 19.84M 19.26M
Depreciation
17.90M 24.10M 19.80M 19.26M
Amortization of Intangibles
- 53.00K 72.00K 37.00K
COGS Growth
- +648.74% +11.65% -13.71%
Gross Income
897.01M (133.22M) 221.12M (92.19M)
Gross Income Growth
- -114.85% +265.98% -141.69%
Gross Profit Margin
+98.04% -11,120.53% +59.57% -247.08%
2021 2022 2023 2024 5-year trend
SG&A Expense
523.48M 539.94M 443.66M 374.37M
Research & Development
420.68M 437.47M 367.50M 301.39M
Other SG&A
102.80M 102.46M 76.16M 72.98M
SGA Growth
+51.31% +3.14% -17.83% -15.62%
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
373.53M (673.16M) (222.54M) (466.57M)
Non Operating Income/Expense
6.00M 22.66M 71.82M 103.90M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
379.53M (650.50M) (150.72M) (362.67M)
Pretax Income Growth
+209.04% -271.40% +76.83% -140.62%
Pretax Margin
+41.48% -54,298.83% -40.60% -971.93%
Income Tax
1.87M (325.00K) 2.89M 3.59M
Income Tax - Current - Domestic
122.00K 685.00K 3.31M 4.07M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
1.75M (1.01M) (424.00K) (484.00K)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
377.66M (650.17M) (153.61M) (366.25M)
Minority Interest Expense
- - - -
-
Net Income
377.66M (650.17M) (153.61M) (366.25M)
Net Income Growth
+208.25% -272.16% +76.37% -138.43%
Net Margin Growth
+41.28% -54,271.70% -41.38% -981.54%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
377.66M (650.17M) (153.61M) (366.25M)
Preferred Dividends
- - - -
-
Net Income Available to Common
377.66M (650.17M) (153.61M) (366.25M)
EPS (Basic)
4.9726 -8.3628 -1.939 -4.3416
EPS (Basic) Growth
+194.00% -268.18% +76.81% -123.91%
Basic Shares Outstanding
75.95M 77.75M 79.22M 84.36M
EPS (Diluted)
4.6977 -8.3628 -1.939 -4.3416
EPS (Diluted) Growth
+188.81% -278.02% +76.81% -123.91%
Diluted Shares Outstanding
80.39M 77.75M 79.22M 84.36M
EBITDA
391.48M (648.99M) (202.70M) (447.31M)
EBITDA Growth
+213.39% -265.78% +68.77% -120.67%
EBITDA Margin
+42.79% -54,172.70% -54.61% -1,198.76%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 78.00
Number of Ratings 30 Current Quarters Estimate -1.175
FY Report Date 12 / 2025 Current Year's Estimate -6.233
Last Quarter’s Earnings -1.17 Median PE on CY Estimate N/A
Year Ago Earnings -4.34 Next Fiscal Year Estimate -4.062
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 25 12 27 26
Mean Estimate -1.18 -1.10 -6.23 -4.06
High Estimates -0.75 -0.87 -5.69 2.63
Low Estimate -1.67 -1.43 -6.86 -6.91
Coefficient of Variance -18.50 -14.93 -4.63 -46.40

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 17 17 16
OVERWEIGHT 0 0 1
HOLD 12 12 12
UNDERWEIGHT 0 0 0
SELL 1 1 1
MEAN Overweight Overweight Overweight

Insider Actions for Crispr Therapeutics Ag - CRSP

Date Name Shares Transaction Value
Mar 25, 2025 Raju Prasad Chief Financial Officer 16,767 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $41.23 per share 691,303.41
Mar 25, 2025 Julianne Bruno Chief Operating Officer 11,250 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 25, 2025 Julianne Bruno Chief Operating Officer 10,544 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $41.23 per share 434,729.12
Mar 25, 2025 Julianne Bruno Chief Operating Officer 12,258 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 25, 2025 Raju Prasad Chief Financial Officer 18,750 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 25, 2025 James R. Kasinger General Counsel and Secretary 84,914 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 25, 2025 Raju Prasad Chief Financial Officer 18,964 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 25, 2025 James R. Kasinger General Counsel and Secretary 18,750 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 25, 2025 James R. Kasinger General Counsel and Secretary 81,729 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $41.23 per share 3,369,686.67
Mar 3, 2025 John T. Greene Director 7,000 Open market or private purchase of non-derivative security Non-derivative transaction at $44.85 per share 313,950.00
Feb 24, 2025 Samarth Kulkarni Chief Executive Officer; Director 171,613 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $55.2 per share 9,473,037.60
Feb 20, 2025 James R. Kasinger General Counsel and Secretary 3,825 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 James R. Kasinger General Counsel and Secretary N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 Samarth Kulkarni Chief Executive Officer; Director 196,901 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $55.05 per share 10,839,400.05
Feb 20, 2025 Samarth Kulkarni Chief Executive Officer; Director 189,973 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $52.8 per share 10,030,574.40
Feb 20, 2025 Samarth Kulkarni Chief Executive Officer; Director 13,250 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 James R. Kasinger General Counsel and Secretary 74,880 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $52.8 per share 3,953,664.00

Crispr Therapeutics Ag in the News